Technical Analysis for NRSN - NeuroSense Therapeutics Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 1.08 | -3.57% | -0.04 |
NRSN closed down 3.57 percent on Monday, July 1, 2024, on 10.57 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| 200 DMA Support | Bullish | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| 20 DMA Support | Bullish | -3.57% |
| Alert | Time |
|---|---|
| 200 DMA Support | about 6 hours ago |
| Possible Inside Day | about 6 hours ago |
| Fell Below 20 DMA | about 10 hours ago |
| Gap Down Partially Closed | about 10 hours ago |
| Gap Down Closed | about 10 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/14/2024
NeuroSense Therapeutics is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include ALS, Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients. Due to the complexity of neurodegenerative diseases, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Disease Neuroscience Alzheimer's Disease Parkinson's Disease Neurodegenerative Diseases Neurodegeneration Senescence Gladstone Institutes
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Disease Neuroscience Alzheimer's Disease Parkinson's Disease Neurodegenerative Diseases Neurodegeneration Senescence Gladstone Institutes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.33 |
| 52 Week Low | 0.4 |
| Average Volume | 134,550 |
| 200-Day Moving Average | 1.07 |
| 50-Day Moving Average | 1.14 |
| 20-Day Moving Average | 1.01 |
| 10-Day Moving Average | 0.94 |
| Average True Range | 0.13 |
| RSI (14) | 53.05 |
| ADX | 20.55 |
| +DI | 20.46 |
| -DI | 20.23 |
| Chandelier Exit (Long, 3 ATRs) | 0.86 |
| Chandelier Exit (Short, 3 ATRs) | 1.09 |
| Upper Bollinger Bands | 1.23 |
| Lower Bollinger Band | 0.79 |
| Percent B (%b) | 0.66 |
| BandWidth | 42.63 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.08 |
| MACD Histogram | 0.0254 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.31 | ||||
| Resistance 3 (R3) | 1.30 | 1.21 | 1.27 | ||
| Resistance 2 (R2) | 1.21 | 1.16 | 1.22 | 1.25 | |
| Resistance 1 (R1) | 1.15 | 1.12 | 1.18 | 1.16 | 1.24 |
| Pivot Point | 1.06 | 1.06 | 1.08 | 1.07 | 1.06 |
| Support 1 (S1) | 1.00 | 1.01 | 1.03 | 1.01 | 0.92 |
| Support 2 (S2) | 0.91 | 0.97 | 0.92 | 0.91 | |
| Support 3 (S3) | 0.85 | 0.91 | 0.89 | ||
| Support 4 (S4) | 0.86 |
